---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-25-000180"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T02:06:31.519299+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M

## Summary
- GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.
- INGREZZA net sales $686.6M (+12% YoY) driven by record quarterly new and total prescriptions.
- CRENESSITY launch generated $98.1M net sales with 540 new patient enrollment start forms.
- FY2025 INGREZZA guidance reaffirmed at $2.50-2.55B; GAAP R&D $1.00-1.02B, SG&A $1.14-1.16B.
- Initiated second Phase 3 trial for direclidine (schizophrenia); osavampator Phase 3 in MDD enrolling.

## SEC filing metadata
- accession: 0000914475-25-000180
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/0000914475-25-000180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/nbix-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-25-000180
- JSON: https://secwatch.observer/filing/0000914475-25-000180.json
- Plain text: https://secwatch.observer/filing/0000914475-25-000180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.